1 in 4 population deaths related to thrombosis (cdc.gov)
25% of thrombosis-associated deaths were considered sudden and therefore could only be prevented by special prevention.
50% of people who undergo VTE will have long-term effects (post-thrombotic syndrome): pain, swelling, limb fever
33% of VTE episode survivors will relapse within 10 years (wtd.org)
Thrombophilias have a low incidence (5-8%) in the general population and are significant among young patients with recurrent thrombosis (Michele G. et al AmJPM, 2010)
ATHI deficiency leads to tolerance in the formation of a blood clot. As a result - uncontrolled thrombosis, thrombosis, thromboembolism.
Protein S deficiency results in an almost 100% risk of developing deep vein thrombosis, especially in young people under 25 years of age. 17% of ischemic strokes in young women - Lupus anticoagulant. (Key W.P.Ng et al. Stroke Res Treat, 2011)
VTE for oncological pathology:
20 to 30% of all primary cases of venous thromboembolism are associated with cancer (Jasmijn F. et al. Blood, 2013)
in 15% of all patients with environmental pathology, symptomatic venous thromboembolism (VTE) is observed annually (Elewa H. et al. Curr treat Options Cardio Med, 2016)
The incidence of VTE in non-Hodgkin's lymphoma patients ranges from 7.9 to 17.1% (Lee Chun Park et al. Thrombosis Research, 2012; Xiao Zhou, MD et al., The American Journal of Medicine 2010)